CureVac NV

1CVAC

Company Profile

  • Business description

    CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company’s other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

  • Contact

    Friedrich-Miescher-Strasse 15
    TubingenBW72076
    DEU

    T: +49 707198830

    E: [email protected]

    https://www.curevac.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    1,088

Stocks News & Analysis

stocks

ASX reporting season wrap: BHP, banks, CSL bloodbath and more

A round up of notable stories and reactions as ASX earnings season continues.
stocks

Stock showdown: How do ASX healthcare giants compare on key investing criteria?

Our healthcare analyst Shane Ponraj helps me compare the moatiness and growth prospects of two sector heavyweights.
stocks

Peak profit for ASX listed insurer

Simplification plan complete, organic growth now the focus.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,234.3055.70-0.60%
CAC 407,969.6931.400.40%
DAX 4024,363.0969.750.29%
Dow JONES (US)45,631.74846.241.89%
FTSE 1009,321.4012.200.13%
HKSE25,339.14234.530.93%
NASDAQ21,496.54396.221.88%
Nikkei 22542,633.2923.120.05%
NZX 50 Index13,042.76151.31-1.15%
S&P 5006,466.9196.741.52%
S&P/ASX 2008,967.4057.00-0.63%
SSE Composite Index3,825.7654.661.45%

Market Movers